The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
ApexOnco Front Page
Recent articles
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.